Exemestane Compared With Tamoxifen in Treating Postmenopausal Women With Breast Cancer
NCT ID: NCT00032136
Last Updated: 2013-08-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
4400 participants
INTERVENTIONAL
2001-12-31
2009-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
PURPOSE: Randomized phase III trial to compare the effectiveness of exemestane with that of tamoxifen in treating postmenopausal women who have undergone surgery to remove early-stage breast cancer.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* Compare the efficacy and tolerability of adjuvant exemestane versus adjuvant tamoxifen in postmenopausal women with early breast cancer.
* Compare the relapse-free survival and overall survival of patients treated with these drugs.
* Compare the incidence of contralateral breast cancer in patients treated with these drugs.
* Compare the safety and long-term tolerability of these drugs in these patients.
* Compare the quality of life of patients treated with these drugs.
OUTLINE: This is a randomized, open-label, multicenter study. Patients are stratified according to estrogen receptor (ER)/progesterone receptor (PgR) status (ER positive vs ER negative/PgR positive vs ER positive/PgR unknown), prior chemotherapy (none vs taxane-based vs anthracycline-based vs other), and nodal status (negative vs 1-3 nodes positive vs 4 or more nodes positive). Patients are randomized to 1 of 2 treatment arms.
* Arm I: Patients receive oral tamoxifen once daily
* Arm II: Patients receive oral exemestane once daily. Treatment in both arms continues for a minimum of 5 years in the absence of disease progression or unacceptable toxicity.
Quality of life is assessed at baseline and at months 3 and 12 during study.
Patients are followed at least annually.
PROJECTED ACCRUAL: Approximately 4,400 patients (2,200 per treatment arm) will be accrued for this study.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
TREATMENT
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
exemestane
tamoxifen citrate
adjuvant therapy
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Histologically or cytologically confirmed early adenocarcinoma of the breast
* Completely excised by surgery with curative intent (R0)
* Any N OR
* Any primary tumor greater than 3 cm OR
* Any primary tumor grade III and greater than 1 cm
* M0
* No positive supraclavicular nodes
* Hormone receptor status:
* Estrogen and/or progesterone receptor positive
PATIENT CHARACTERISTICS:
Age:
* Any age
* See Menopausal status
Sex:
* Female
Menopausal status:
* Postmenopausal
* Any age with bilateral oophorectomy or amenorrhea for at least 5 years OR
* Age 50 or over:
* Natural amenorrhea for at least 1 year OR
* Chemotherapy-induced amenorrhea for at least 2 years OR
* Radiation-induced amenorrhea (at least 3 months since prior radiotherapy) OR
* Under age 50:
* If amenorrheic for less than 5 years (any cause) or prior hysterectomy without bilateral surgical oophorectomy, follicle-stimulating hormone must be assayed to confirm postmenopausal status
Performance status:
* ECOG 0-2
Life expectancy:
* Not specified
Hematopoietic:
* Platelet count greater than 100,000/mm3
* WBC greater than 3,000/mm3
Hepatic:
* SGOT or SGPT less than 2.5 times upper limit of normal (ULN)
Renal:
* Creatinine less than 1.5 times ULN
Cardiovascular:
* No uncontrolled cardiac disease
* No unstable angina
* No congestive heart failure or arrhythmia requiring medical therapy
* No myocardial infarction within the past 3 months
Other:
* No severe osteoporosis
* No other malignancies within the past 5 years except adequately treated carcinoma in situ of the cervix or basal cell skin cancer
* No other serious concurrent disease that would preclude study
* No psychiatric disorders that would preclude study
PRIOR CONCURRENT THERAPY:
Biologic therapy:
* Not specified
Chemotherapy:
* No prior neoadjuvant chemotherapy
* No more than 10 weeks since completion of prior adjuvant chemotherapy
Endocrine therapy:
* No prior adjuvant hormonal therapy for breast cancer
* No prior neoadjuvant hormonal therapy (prior to surgery) for duration of more than 4 weeks
* At least 4 weeks since prior hormone replacement therapy
Radiotherapy:
* Not specified
Surgery:
* See Disease Characteristics
* No more than 10 weeks since completion of curative surgery
Other:
* No other concurrent investigational agents or participation in another clinical study (except adjuvant cytotoxic chemotherapy studies)
* Concurrent bisphosphonates allowed
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Cancer Research Campaign Clinical Trials Centre
OTHER
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Daniel Rea, MD
Role: STUDY_CHAIR
City Hospital Birmingham
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
City Hospital - Birmingham
Birmingham, England, United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Hadji P, Asmar L, van Nes JG, Menschik T, Hasenburg A, Kuck J, Nortier JW, van de Velde CJ, Jones SE, Ziller M. The effect of exemestane and tamoxifen on bone health within the Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial: a meta-analysis of the US, German, Netherlands, and Belgium sub-studies. J Cancer Res Clin Oncol. 2011 Jun;137(6):1015-25. doi: 10.1007/s00432-010-0964-y. Epub 2010 Dec 18.
van de Velde CJ, Rea D, Seynaeve C, Putter H, Hasenburg A, Vannetzel JM, Paridaens R, Markopoulos C, Hozumi Y, Hille ET, Kieback DG, Asmar L, Smeets J, Nortier JW, Hadji P, Bartlett JM, Jones SE. Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial. Lancet. 2011 Jan 22;377(9762):321-31. doi: 10.1016/S0140-6736(10)62312-4.
Kieback DG, Harbeck N, Bauer W, Hadji P, Weyer G, Menschik T, Hasenburg A. Endometrial effects of exemestane compared to tamoxifen within the Tamoxifen Exemestane Adjuvant Multicenter (TEAM) trial: results of a prospective gynecological ultrasound substudy. Gynecol Oncol. 2010 Dec;119(3):500-5. doi: 10.1016/j.ygyno.2010.08.006. Epub 2010 Sep 15.
Hadji P, Ziller M, Kieback DG, Dornoff W, Tessen HW, Menschik T, Kuck J, Melchert F, Hasenburg A. Effects of exemestane and tamoxifen on bone health within the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial: results of a German, 12-month, prospective, randomised substudy. Ann Oncol. 2009 Jul;20(7):1203-9. doi: 10.1093/annonc/mdn762. Epub 2009 Feb 13.
Hadji P, Ziller M, Kieback DG, Menschik T, Kalder M, Kuck J, Hasenburg A. The effect of exemestane or tamoxifen on markers of bone turnover: results of a German sub-study of the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial. Breast. 2009 Jun;18(3):159-64. doi: 10.1016/j.breast.2009.03.003. Epub 2009 Apr 11.
Beltran-Bless AA, Pond GR, Bayani J, Barker SL, Spears M, Mallon E, Taylor KJ, Hasenburg A, Markopoulos C, Dirix L, Meershoek-Klein Kranenbarg E, van de Velde CJH, Rea DW, Vandermeer L, Hilton J, Bartlett JMS, Clemons M. Does RSClin provide additional information over classic clinico-pathologic scores (PREDICT 2.1, INFLUENCE 2.0, CTS5)? Breast. 2025 Oct;83:104528. doi: 10.1016/j.breast.2025.104528. Epub 2025 Jul 4.
Bayani J, Kornaga EN, Crozier C, Jang GH, Bathurst L, Kalatskaya I, Trinh QM, Yao CQ, Livingstone J, Boutros PC, Spears M, McPherson JD, Stein LD, Rea D, Bartlett JMS. Identification of Distinct Prognostic Groups: Implications for Patient Selection to Targeted Therapies Among Anti-Endocrine Therapy-Resistant Early Breast Cancers. JCO Precis Oncol. 2019 Dec;3:1-13. doi: 10.1200/PO.18.00373.
Derks MGM, Bastiaannet E, van de Water W, de Glas NA, Seynaeve C, Putter H, Nortier JWR, Rea D, Hasenburg A, Markopoulos C, Dirix LY, Portielje JEA, van de Velde CJH, Liefers GJ. Impact of age on breast cancer mortality and competing causes of death at 10 years follow-up in the adjuvant TEAM trial. Eur J Cancer. 2018 Aug;99:1-8. doi: 10.1016/j.ejca.2018.04.009. Epub 2018 Jun 6.
Derks MGM, Blok EJ, Seynaeve C, Nortier JWR, Kranenbarg EM, Liefers GJ, Putter H, Kroep JR, Rea D, Hasenburg A, Markopoulos C, Paridaens R, Smeets JBE, Dirix LY, van de Velde CJH. Adjuvant tamoxifen and exemestane in women with postmenopausal early breast cancer (TEAM): 10-year follow-up of a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2017 Sep;18(9):1211-1220. doi: 10.1016/S1470-2045(17)30419-9. Epub 2017 Jul 18.
Bartlett JM, Brookes CL, Piper T, van de Velde CJ, Stocken D, Lyttle N, Hasenburg A, Quintayo MA, Kieback DG, Putter H, Markopoulos C, Kranenbarg EM, Mallon EA, Dirix LY, Seynaeve C, Rea DW. Do type 1 receptor tyrosine kinases inform treatment choice? A prospectively planned analysis of the TEAM trial. Br J Cancer. 2013 Oct 29;109(9):2453-61. doi: 10.1038/bjc.2013.609. Epub 2013 Oct 3.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CDR0000069260
Identifier Type: REGISTRY
Identifier Source: secondary_id
EU-20149
Identifier Type: -
Identifier Source: secondary_id
ISRCTN75225940
Identifier Type: -
Identifier Source: secondary_id
CRC-TU-TEAM
Identifier Type: -
Identifier Source: org_study_id